Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005592 · ClinicalTrials.gov registry record · Phase 2
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00005592: Completed Phase 2 study, sponsored by University of Alabama at Birmingham.
NCT00005592 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 23 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005592, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radiation to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of rituximab and ibritumomab tiuxetan in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
Interventions
- BIOLOGICAL rituximab
- RADIATION indium In 111 ibritumomab tiuxetan
- BIOLOGICAL 90-Y-ibritumomab tiuxetan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 1999-11 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00005592 record still lists
NCT00005592 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which rituximab is the first listed.
NCT00005592 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005592 about?
NCT00005592 is a clinical study titled "Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radiation to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of rituximab and ibritumomab tiuxetan in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
What is the current status of trial NCT00005592?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 1999-11. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00005592?
The interventions under investigation include: rituximab (BIOLOGICAL), indium In 111 ibritumomab tiuxetan (RADIATION), 90-Y-ibritumomab tiuxetan (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005592?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00005592's enrollment target sits among peer trials
23 1784th of 2000 higher than 211 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia